Share-based Payment Arrangement, Expense of Sage Therapeutics, Inc. from 30 Jun 2013 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Sage Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2013 to 30 Jun 2025.
  • Sage Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $8,733,000, a 49% decline year-over-year.
  • Sage Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $39,299,000, a 46% decline year-over-year.
  • Sage Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $54,504,000, a 26% decline from 2023.
  • Sage Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $73,367,000, a 19% increase from 2022.
  • Sage Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $61,602,000, a 41% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Sage Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $39,299,000 $8,733,000 -$8,434,000 -49% 01 Apr 2025 30 Jun 2025 10-Q 30 Jul 2025 2025 Q2
Q1 2025 $47,733,000 $6,927,000 -$6,771,000 -49% 01 Jan 2025 31 Mar 2025 10-Q 29 Apr 2025 2025 Q1
Q4 2024 $54,504,000 $9,432,000 -$3,513,000 -27% 01 Oct 2024 31 Dec 2024 10-K 11 Feb 2025 2024 FY
Q3 2024 $58,017,000 $14,207,000 -$14,484,000 -50% 01 Jul 2024 30 Sep 2024 10-Q 29 Oct 2024 2024 Q3
Q2 2024 $72,501,000 $17,167,000 +$5,474,000 +47% 01 Apr 2024 30 Jun 2024 10-Q 30 Jul 2025 2025 Q2
Q1 2024 $67,027,000 $13,698,000 -$6,340,000 -32% 01 Jan 2024 31 Mar 2024 10-Q 29 Apr 2025 2025 Q1
Q4 2023 $73,367,000 $12,945,000 -$2,299,000 -15% 01 Oct 2023 31 Dec 2023 10-K 11 Feb 2025 2024 FY
Q3 2023 $75,666,000 $28,691,000 +$15,522,000 +118% 01 Jul 2023 30 Sep 2023 10-Q 29 Oct 2024 2024 Q3
Q2 2023 $60,144,000 $11,693,000 -$2,943,000 -20% 01 Apr 2023 30 Jun 2023 10-Q 31 Jul 2024 2024 Q2
Q1 2023 $63,087,000 $20,038,000 +$1,485,000 +8% 01 Jan 2023 31 Mar 2023 10-Q 25 Apr 2024 2024 Q1
Q4 2022 $61,602,000 $15,244,000 -$5,404,000 -26% 01 Oct 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
Q3 2022 $67,006,000 $13,169,000 -$21,173,000 -62% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $88,179,000 $14,636,000 -$13,027,000 -47% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $101,206,000 $18,553,000 -$3,423,000 -16% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q4 2021 $104,629,000 $20,648,000 -$96,000 -0.46% 01 Oct 2021 31 Dec 2021 10-K 14 Feb 2024 2023 FY
Q3 2021 $104,725,000 $34,342,000 +$14,234,000 +71% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $90,491,000 $27,663,000 +$3,631,000 +15% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $86,860,000 $21,976,000 -$9,134,000 -29% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $95,994,000 $20,744,000 -$9,935,000 -32% 01 Oct 2020 31 Dec 2020 10-K 16 Feb 2023 2022 FY
Q3 2020 $105,929,000 $20,108,000 -$23,561,000 -54% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $129,490,000 $24,032,000 -$10,735,000 -31% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $140,225,000 $31,110,000 -$13,006,000 -29% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $153,231,000 $30,679,000 -$961,000 -3% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $154,192,000 $43,669,000 +$18,191,000 +71% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $136,001,000 $34,767,000 +$5,739,000 +20% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $130,262,000 $44,116,000 +$28,299,000 +179% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $101,963,000 $31,640,000 +$21,395,000 +209% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
Q3 2018 $80,568,000 $25,478,000 +$15,747,000 +162% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $64,821,000 $29,028,000 +$19,678,000 +210% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $45,143,000 $15,817,000 +$9,609,000 +155% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1
Q4 2017 $35,534,000 $10,245,000 +$152,000 +1.5% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
Q3 2017 $35,382,000 $9,731,000 +$4,983,000 +105% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $30,399,000 $9,350,000 +$4,885,000 +109% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $25,514,000 $6,208,000 +$2,494,000 +67% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2018 2018 Q1
Q4 2016 $23,020,000 $10,093,000 +$6,007,000 +147% 01 Oct 2016 31 Dec 2016 10-K 19 Feb 2019 2018 FY
Q3 2016 $17,013,000 $4,748,000 +$341,000 +7.7% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017 2017 Q3
Q2 2016 $16,672,000 $4,465,000 -$933,000 -17% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $17,605,000 $3,714,000 +$2,365,000 +175% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $15,240,000 $4,086,000 +$2,759,000 +208% 01 Oct 2015 31 Dec 2015 10-K 22 Feb 2018 2017 FY
Q3 2015 $12,481,000 $4,407,000 +$3,717,000 +539% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $8,764,000 $5,398,000 +$5,063,000 +1511% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $3,701,000 $1,349,000 +$1,189,000 +743% 01 Jan 2015 31 Mar 2015 10-Q 06 May 2016 2016 Q1
Q4 2014 $2,512,000 $1,327,000 01 Oct 2014 31 Dec 2014 10-K 24 Feb 2017 2016 FY
Q3 2014 $690,000 +$670,000 03 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $335,000 +$327,000 01 Apr 2014 30 Jun 2014 10-Q 12 Aug 2015 2015 Q2
Q1 2014 $160,000 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015 2015 Q1
Q3 2013 $20,000* 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2014 2014 Q3
Q2 2013 $8,000* 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014 2014 Q2

Sage Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $54,504,000 -$18,863,000 -26% 01 Jan 2024 31 Dec 2024 10-K 11 Feb 2025 2024 FY
2023 $73,367,000 +$11,765,000 +19% 01 Jan 2023 31 Dec 2023 10-K 11 Feb 2025 2024 FY
2022 $61,602,000 -$43,027,000 -41% 01 Jan 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
2021 $104,629,000 +$8,635,000 +9% 01 Jan 2021 31 Dec 2021 10-K 14 Feb 2024 2023 FY
2020 $95,994,000 -$57,237,000 -37% 01 Jan 2020 31 Dec 2020 10-K 16 Feb 2023 2022 FY
2019 $153,231,000 +$51,268,000 +50% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $101,963,000 +$66,429,000 +187% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $35,534,000 +$12,514,000 +54% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $23,020,000 +$7,780,000 +51% 01 Jan 2016 31 Dec 2016 10-K 19 Feb 2019 2018 FY
2015 $15,240,000 +$12,728,000 +507% 01 Jan 2015 31 Dec 2015 10-K 22 Feb 2018 2017 FY
2014 $2,512,000 +$2,451,000 +4018% 01 Jan 2014 31 Dec 2014 10-K 24 Feb 2017 2016 FY
2013 $61,000 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.